Department of Radiation Oncology, University Hospital Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany.
Institute of Biometry and Medical Informatics, University Hospital Magdeburg, Magdeburg, Germany.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4817-4824. doi: 10.1007/s00432-022-04411-5. Epub 2022 Oct 16.
ALBI and IBI are new scores to evaluate the liver function in patients with hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the prognostic abilities of those scores in patients treated with interstitial brachytherapy (iBT).
190 patients treated with iBT between 01.01.2006 and 01.01.2018 were included in this study. The clinical target dose was 15 Gy. The patients were all in Child-Pugh stadium A or B and across the Barcelona Clinic Liver Cancer (BCLC) Stages 0-C. Retrospectively ALBI and IBI were calculated pre- and post-therapeutic until 6 months after iBT. Hazards ratios were calculated, and p values corrected using the false discovery rate according to Benjamini and Hochberg.
The median overall survival was 23.5 months (CI 19-28.5 months), and the median progression-free survival was 7.5 months (CI 6-9 months). Elevated ALBI showed a significantly higher risk to die with a hazard ratio (HR) of 2.010 (ALBI 2 vs. 1) and 4082 (ALBI 3 vs. 1), respectively. The IBI did also show a higher risk with an HR of 1.816 (IBI 1 vs. 0) and 4608 (IBI 2 vs. 0), respectively. Even 3 months after therapy elevated ALBI and IBI showed poor overall survival. Concerning progression-free survival, ALBI and IBI could not provide any relevant additional information.
ALBI and IBI are useful tools to predict the overall survival in patients treated with iBT and might be helpful to assign the patients to the appropriate therapy.
ALBI 和 IBI 是用于评估肝细胞癌（HCC）患者肝功能的新评分。本研究旨在评估这些评分在接受间质内近距离放射治疗（iBT）的患者中的预后能力。
本研究纳入了 190 例于 2006 年 1 月 1 日至 2018 年 1 月 1 日期间接受 iBT 治疗的患者。临床靶剂量为 15 Gy。所有患者均处于 Child-Pugh 分级 A 或 B 级，巴塞罗那临床肝癌（BCLC）分期为 0 期至 C 期。回顾性地计算了治疗前后（直至 iBT 后 6 个月）的 ALBI 和 IBI。计算了风险比，并根据 Benjamini 和 Hochberg 的 False Discovery Rate 对 p 值进行了校正。
中位总生存期为 23.5 个月（95%CI 19-28.5 个月），中位无进展生存期为 7.5 个月（95%CI 6-9 个月）。ALBI 升高患者死亡风险显著升高，风险比（HR）分别为 2.010（ALBI 2 与 1）和 4082（ALBI 3 与 1）。IBI 也显示出更高的风险，HR 分别为 1.816（IBI 1 与 0）和 4608（IBI 2 与 0）。即使在治疗后 3 个月，ALBI 和 IBI 升高仍与总体生存率差相关。关于无进展生存期，ALBI 和 IBI 不能提供任何相关的额外信息。
ALBI 和 IBI 是用于评估接受 iBT 治疗的患者总体生存率的有用工具，可能有助于将患者分配到适当的治疗方案。
